Keystone Financial Group Immunity Bio, Inc. Transaction History
Keystone Financial Group
- $1.07 Billion
- Q2 2025
A detailed history of Keystone Financial Group transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Keystone Financial Group holds 10,000 shares of IBRX stock, worth $24,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$24,500% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
277Shares Held
121MCall Options Held
2.49MPut Options Held
3.14M-
Vanguard Group Inc Valley Forge, PA21.8MShares$53.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$28 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC8.76MShares$21.5 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.76MShares$19 Million0.36% of portfolio
-
Jane Street Group, LLC New York, NY7.72MShares$18.9 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $981M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...